Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators. Serruys PW, et al. Among authors: zalewski a. Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899. Epub 2008 Sep 1. Circulation. 2008. PMID: 18765397 Clinical Trial.
First-in-man prospective evaluation of temporal changes in coronary plaque composition by in vivo intravascular ultrasound radiofrequency data analysis: an Integrated Biomarker and Imaging Study (IBIS) substudy.
Rodriguez-Granillo GA, Serruys PW, McFadden EP, van Mieghem CA, Goedhart D, Bruining N, van der Steen AF, van der Giessen WJ, de Jaegere P, Vince DG, Sianos G, Kaplow J, Zalewski A, de Feyter PJ. Rodriguez-Granillo GA, et al. Among authors: zalewski a. EuroIntervention. 2005 Nov;1(3):282-8. EuroIntervention. 2005. PMID: 19758918
Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology.
Van Mieghem CA, Bruining N, Schaar JA, McFadden E, Mollet N, Cademartiri F, Mastik F, Ligthart JM, Granillo GA, Valgimigli M, Sianos G, van der Giessen WJ, Backx B, Morel MA, Van Es GA, Sawyer JD, Kaplow J, Zalewski A, van der Steen AF, de Feyter P, Serruys PW. Van Mieghem CA, et al. Among authors: zalewski a. Int J Cardiovasc Imaging. 2005 Aug;21(4):425-41. doi: 10.1007/s10554-004-7986-y. Int J Cardiovasc Imaging. 2005. PMID: 16047125
Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS).
Van Mieghem CA, McFadden EP, de Feyter PJ, Bruining N, Schaar JA, Mollet NR, Cademartiri F, Goedhart D, de Winter S, Granillo GR, Valgimigli M, Mastik F, van der Steen AF, van der Giessen WJ, Sianos G, Backx B, Morel MA, van Es GA, Zalewski A, Serruys PW. Van Mieghem CA, et al. Among authors: zalewski a. J Am Coll Cardiol. 2006 Mar 21;47(6):1134-42. doi: 10.1016/j.jacc.2005.09.075. Epub 2006 Feb 23. J Am Coll Cardiol. 2006. PMID: 16545642 Free article. Clinical Trial.
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
García-García HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Nesto RW, Serruys PW; APPROACH study group. García-García HM, et al. Int J Cardiovasc Imaging. 2012 Mar;28(3):455-65. doi: 10.1007/s10554-011-9836-z. Epub 2011 Feb 27. Int J Cardiovasc Imaging. 2012. PMID: 21359834 Free PMC article. Clinical Trial.
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group. Ratner RE, et al. Among authors: zalewski a. Am Heart J. 2008 Dec;156(6):1074-9. doi: 10.1016/j.ahj.2008.07.025. Epub 2008 Oct 11. Am Heart J. 2008. PMID: 19033001 Clinical Trial.
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Wilensky RL, et al. Among authors: zalewski a. Nat Med. 2008 Oct;14(10):1059-66. doi: 10.1038/nm.1870. Epub 2008 Sep 21. Nat Med. 2008. PMID: 18806801 Free PMC article.
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators. Mohler ER 3rd, et al. Among authors: zalewski a. J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079. J Am Coll Cardiol. 2008. PMID: 18436114 Free article. Clinical Trial.
Peripheral artery disease, biomarkers, and darapladib.
Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER 3rd. Berger JS, et al. Among authors: zalewski a. Am Heart J. 2011 May;161(5):972-8. doi: 10.1016/j.ahj.2011.01.017. Am Heart J. 2011. PMID: 21570531 Free PMC article. Clinical Trial.
272 results